These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30707664)

  • 1. BRCA Testing Dichotomy in Saudi Arabia.
    Abusanad A
    J Glob Oncol; 2019 Jan; 5():1-2. PubMed ID: 30707664
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic Testing After Previous BRCA Testing: A Case Study.
    Ward M
    Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
    J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
    [No Abstract]   [Full Text] [Related]  

  • 4. BRCA screening.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
    [No Abstract]   [Full Text] [Related]  

  • 5. The case against BRCA 1 and 2 testing.
    Lin C; Sasaki T; Strumwasser A; Harken A
    Surgery; 2011 Jun; 149(6):731-4. PubMed ID: 21621683
    [No Abstract]   [Full Text] [Related]  

  • 6. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
    Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
    Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA to the future: towards best testing practice in the era of personalised healthcare.
    Capoluongo E
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S1-2. PubMed ID: 27514838
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer.
    Blazer KR; Slavin T; Weitzel JN
    JAMA Oncol; 2016 Jun; 2(6):723-4. PubMed ID: 26869327
    [No Abstract]   [Full Text] [Related]  

  • 9. Finding all BRCA pathogenic mutation carriers: best practice models.
    Hoogerbrugge N; Jongmans MC
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.
    Katki HA; Gail MH; Greene MH
    Lancet Oncol; 2007 Dec; 8(12):1042-1043. PubMed ID: 18054868
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
    Abulkhair O; Al Balwi M; Makram O; Alsubaie L; Faris M; Shehata H; Hashim A; Arun B; Saadeddin A; Ibrahim E
    J Glob Oncol; 2018 Aug; 4():1-9. PubMed ID: 30199306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
    Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA testing is important for our patients.
    Anderson BO; Javid SH; Calhoun KE; Byrd DR
    Surgery; 2012 Apr; 151(4):637-8. PubMed ID: 22306834
    [No Abstract]   [Full Text] [Related]  

  • 14. BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
    Kehl KL; Giordano SH
    JAMA Oncol; 2016 May; 2(5):688-9. PubMed ID: 27244682
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.
    Sinilnikova OM; Mazoyer S; Bonnardel C; Lynch HT; Narod SA; Lenoir GM
    Fam Cancer; 2006; 5(1):15-20. PubMed ID: 16528604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic counseling for breast cancer risk: how did we get here and where are we going?
    Lang KA
    Expert Rev Mol Diagn; 2013 Jul; 13(6):541-51. PubMed ID: 23895125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
    Riahi A; Chabouni-Bouhamed H; Kharrat M
    Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic testing in patients at risk for carcinoma of the breast].
    Kiechle M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
    [No Abstract]   [Full Text] [Related]  

  • 20. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
    JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.